MedTrace Logo

PSTB100 Study in Healthy Adult Subjects

NCT07702279 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2026-07-16

No results posted yet for this study

Summary

This study is a randomized, double-blind, placebo-controlled, dose-escalation， first-in-human clinical trial in healthy adults, designed to assess the safety, tolerability, and PK characteristics of PSTB100 tablets.

Conditions

  • Healthy Adult Subjects

Interventions

DRUG

PSTB100 tablets

PSTB100 tablets: 0.25 mg, 1 mg, 3 mg, 10 mg, 20 mg.

DRUG

PSTB100 tablets

2 mg once daily， 5 mg once daily， 10 mg once daily

Sponsors & Collaborators

  • Prospect Therapeutics (Nanjing) Limited

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-07-28
Primary Completion
2027-06-12
Completion
2027-09-06

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07702279 on ClinicalTrials.gov